By admin 
CureSearch for Children’s Cancer, a leading global nonprofit dedicated to accelerating the development of new pediatric cancer treatments, has announced the recipient of its prestigious 2026 Catapult Award. Dr. Robbie Majzner, a renowned physician-scientist at the Dana-Farber Cancer Institute, has been awarded a $2 million investment to spearhead a Phase I clinical trial for a groundbreaking chimeric antigen receptor (CAR) T-cell therapy. This initiative, co-funded by the Jeff Gordon Children’s Foundation, represents a significant leap forward in the fight against high-risk neuroblastoma, a disease that has long remained one of the most challenging obstacles in pediatric oncology.
The funding is specifically earmarked to transition a novel laboratory discovery into the clinical setting, addressing a critical "bottleneck" in medical research where promising therapies often stall due to lack of financial support for early-phase human trials. By targeting relapsed and refractory neuroblastoma, Dr. Majzner’s team aims to provide a lifeline to children and young adults for whom standard treatments have failed.
The Critical Need: Understanding Neuroblastoma and its Impact
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It is the most frequent extracranial solid tumor in children, accounting for approximately 7% to 10% of all childhood cancer diagnoses. Despite its relatively low incidence compared to adult cancers, its lethality is disproportionate, contributing to more than 10% of all pediatric cancer deaths.
For patients diagnosed with high-risk neuroblastoma, the prognosis remains somber. Current statistics indicate that the five-year survival rate for high-risk cases lingers below 50%. Standard treatment protocols are notoriously aggressive, often involving a combination of high-dose chemotherapy, multiple surgeries, radiation therapy, and stem cell transplants. Even when these interventions are successful in achieving remission, the long-term side effects—ranging from hearing loss and kidney dysfunction to secondary cancers and cognitive impairments—can be life-altering for survivors.
The relapsed or refractory setting is particularly dire. Once neuroblastoma returns after initial treatment or fails to respond to induction therapy, the medical community has few proven options to offer. It is within this high-stakes environment that Dr. Majzner’s research seeks to intervene, utilizing the body’s own immune system to identify and destroy malignant cells that have evaded traditional therapies.
The Evolution of CAR T-Cell Therapy in Solid Tumors
CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, such as certain types of leukemia and lymphoma. The process involves extracting a patient’s T-cells—a type of white blood cell essential for immune response—and genetically engineering them in a laboratory to express chimeric antigen receptors. These receptors allow the T-cells to recognize and bind to specific proteins on the surface of cancer cells. Once infused back into the patient, these "living drugs" multiply and launch a targeted attack on the tumor.
However, replicating the success of CAR T-cell therapy in solid tumors, such as neuroblastoma, has proven exceptionally difficult. Unlike blood cancers, solid tumors create a hostile microenvironment that can suppress immune activity. Furthermore, solid tumors often present physical barriers that prevent T-cells from infiltrating the tumor mass. Perhaps the most significant hurdle is "T-cell exhaustion," a state where the engineered cells become fatigued and lose their ability to fight the cancer shortly after entering the body.
Dr. Majzner’s research focuses on overcoming these specific limitations. His team is targeting GD2, a sugar-fat molecule (ganglioside) that is overexpressed on the surface of neuroblastoma cells. While GD2 has been a target for immunotherapy for years, previous CAR T-cell attempts have struggled with durability.
Scientific Innovation: The Role of ZAP70
The innovation at the heart of the 2026 Catapult Award is a redesigned CAR architecture. Traditional CAR T-cells utilize a signaling domain known as CD3-zeta to activate the T-cell upon contact with a cancer cell. Dr. Majzner’s team has replaced or augmented this with a novel signaling protein called ZAP70.
In preclinical models, this "next-generation" CAR T-cell has shown a remarkable ability to resist exhaustion. By modifying the internal signaling pathways of the T-cell, the researchers have created a cell that remains active for longer periods, allowing for a sustained and more potent attack against the neuroblastoma. Furthermore, the redesigned cells demonstrated a potentially improved safety profile, reducing the risk of "off-target" effects that can occur when T-cells attack healthy tissues that express low levels of the target antigen.
The upcoming Phase I clinical trial will be the first time this specific ZAP70-enhanced CAR T-cell therapy is tested in humans. The primary objectives of the study will be to evaluate the safety of the treatment, determine the optimal dosage, and observe the therapy’s persistence within the patient’s bloodstream.
The Catapult Award: Bridging the Translational Gap
The CureSearch Catapult Award was established to address the "Valley of Death" in drug development—the period between the discovery of a promising molecule or mechanism in the lab and the initiation of clinical trials. Translational research is notoriously expensive and high-risk, causing many pharmaceutical companies to shy away from pediatric-specific projects due to the smaller market size compared to adult cancers.
"One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," stated Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
The $2 million grant provides the necessary infrastructure and regulatory support to launch the trial at Dana-Farber Cancer Institute, one of the world’s leading centers for pediatric cancer care. This investment is augmented by the partnership with the Jeff Gordon Children’s Foundation, an organization founded by the four-time NASCAR champion that has been a stalwart supporter of pediatric oncology for over two decades.
Chronology of Development and Trial Timeline
The path to the 2026 Catapult Award has been a multi-year journey of rigorous scientific inquiry:
- Discovery Phase (Pre-2022): Dr. Majzner and his colleagues identified the specific signaling limitations of first- and second-generation GD2 CAR T-cells.
- Engineering and Lab Validation (2022-2024): The team developed the ZAP70-modified CAR architecture and tested it in vitro (cell cultures) and in vivo (mouse models). These studies showed superior anti-tumor activity and cell longevity compared to existing models.
- Award Selection (2025): CureSearch’s Scientific Advisory Board, comprised of leading experts in oncology, selected Dr. Majzner’s project from a competitive pool of applicants based on its potential for immediate clinical impact.
- Clinical Trial Launch (Expected 2026): With the funding secured, the team will finalize FDA regulatory filings, including an Investigational New Drug (IND) application, to begin enrolling pediatric and young adult patients for the Phase I trial.
The trial is expected to enroll a small cohort of patients initially to monitor for cytokine release syndrome (CRS) and neurotoxicity—common side effects of CAR T-cell therapies—before expanding to assess preliminary efficacy.
Official Responses and Implications for the Field
The medical community has reacted with optimism to the announcement. Dr. Robbie Majzner emphasized the transformative nature of the funding, noting that current GD2-targeted therapies often fail when the disease burden is high.
"Current GD2 CAR T cells only work in patients with small amounts of disease," Dr. Majzner explained. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Beyond neuroblastoma, the success of this trial could have far-reaching implications. GD2 is also expressed in other pediatric cancers, such as osteosarcoma and certain types of brain tumors (including DIPG). If the ZAP70 signaling modification proves effective in neuroblastoma, it could serve as a blueprint for treating a wide array of solid tumors that have previously been resistant to immunotherapy.
Furthermore, the collaboration between Dana-Farber, CureSearch, and the Jeff Gordon Children’s Foundation highlights a growing trend in "venture philanthropy," where non-profit organizations take an active role in funding high-stakes clinical development to de-risk projects for future commercial investment.
Conclusion and Future Outlook
The 2026 CureSearch Catapult Award represents more than just a financial transaction; it is a strategic intervention in the landscape of pediatric medicine. As Dr. Majzner’s team prepares for the upcoming clinical trial, the focus remains squarely on the children and families who currently face a lack of viable options.
While the road from Phase I to full regulatory approval is long, the transition of this next-generation CAR T-cell therapy into the clinic is a milestone of hope. By focusing on the fundamental biological hurdles of T-cell exhaustion and solid tumor resistance, this research may finally unlock the potential of immunotherapy for the thousands of children diagnosed with neuroblastoma each year. The coming months will be critical as the team at Dana-Farber moves toward the first patient enrollment, potentially changing the standard of care for pediatric solid tumors forever.
